Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/68076
Registo completo
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Silva, Maria Daniela | por |
dc.contributor.author | Oliveira, Hugo Alexandre Mendes | por |
dc.contributor.author | Faustino, Alberta | por |
dc.contributor.author | Sillankorva, Sanna | por |
dc.date.accessioned | 2020-11-09T19:30:40Z | - |
dc.date.available | 2020-11-09T19:30:40Z | - |
dc.date.issued | 2020-12 | - |
dc.identifier.citation | Silva, Maria Daniela; Oliveira, Hugo; Faustino, Alberta; Sillankorva, Sanna, Characterization of MSlys, the endolysin of Streptococcus pneumoniaephage MS1. Biotechnology Reports, 28(e00547), 2020 | por |
dc.identifier.issn | 2215-017X | por |
dc.identifier.uri | https://hdl.handle.net/1822/68076 | - |
dc.description.abstract | Despite the use of pneumococcal conjugate vaccines, the number of infections related to Streptococcus pneumoniae continues to be alarming. Herein, we identified, characterized the MSlys endolysin encoded in the phage MS1. We further tested its antimicrobial efficacy against planktonic and biofilm cells, assessing the culturability of cells and biofilm structure by scanning electron microscopy, and confocal laser scanning microscopy. The modular MSlys endolysin consists of an amidase catalytic domain and a choline-binding domain. MSlys is active against isolates of children with otitis media, and conditions close to those found in the middle ear. Treatment with MSlys (2h, 4 µM) reduced planktonic cultures by 3.5 log10 CFU/mL, and 24- and 48-h-old biofilms by 1.5 and 1.8 log10 CFU/mL, respectively. Imaging of the biofilms showed thinner and damaged structures compared to control samples. The recombinantly expressed MSlys may be a suitable candidate for treating pneumococcal infections, including otitis media. | por |
dc.description.sponsorship | MDS acknowledges the Portuguese Foundation for Science and Technology (FCT) grant (SFRH/BD/128825/2017). This study was supported by the Portuguese Foundation for Science and Technology (FCT) under the scope of the strategic funding of UID/BIO/04469/2019 unit and BioTecNorte operation (NORTE-01-0145-FEDER-000004) funded by the European Regional Development Fund under the scope of Norte2020 - Programa Operacional Regional do Norte. This project also received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 713640. This study was also supported by the grant PTDC/CVT-CVT/29628/2017 [POCI-01-0145-FEDER-029628]. | por |
dc.language.iso | eng | por |
dc.publisher | Elsevier BV | por |
dc.relation | info:eu-repo/grantAgreement/EC/H2020/713640/EU | por |
dc.relation | SFRH/BD/128825/2017 | por |
dc.relation | UID/BIO/04469/2019 | por |
dc.rights | openAccess | por |
dc.subject | Antibacterial | por |
dc.subject | Biofilm | por |
dc.subject | Endolysin | por |
dc.subject | MSlys | por |
dc.subject | Streptococcus pneumoniae | por |
dc.title | Characterization of MSlys, the endolysin of Streptococcus pneumoniaephage MS1 | por |
dc.type | article | - |
dc.peerreviewed | yes | por |
dc.relation.publisherversion | https://www.journals.elsevier.com/biotechnology-reports | por |
dc.comments | CEB53958 | por |
oaire.citationVolume | 28 | por |
dc.date.updated | 2020-11-07T11:11:30Z | - |
dc.identifier.doi | 10.1016/j.btre.2020.e00547 | por |
dc.description.publicationversion | info:eu-repo/semantics/publishedVersion | - |
sdum.journal | Biotechnology Reports | por |
Aparece nas coleções: | CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
document_53958_1.pdf | 4,65 MB | Adobe PDF | Ver/Abrir |